Everlife Biomed Co. Ltd.
Establishing a novel immune-privileged microenvironment and clinical treatment platform
Everlife Biomed Co. Ltd. is a high-tech innovative enterprise with developing new cell therapy and technology as the main missions. Starting from Tsinghua university, the founding team of the company was led by Professor Kehkooi Kee and Dr. Jianlin Liang at School of Medicine ,Tsinghua University. The company was jointly established by the Global Health Industry Innovation Center (GHIC) in 2019. The research and development headquarter of the company is located in Beijing and more than 80% are elite talents who have received master adoctoral training and excel in cell therapy and clinical application.
Aiming at developing the innovative immune-privileged technology into clinical application, the company has focused on three areas: autoimmune diseases, transplantation treatment and male assisted reproduction. Currently, these product in the development pipelines are:
1. rheumatoid arthritis cell injection #raSC-1,
2. immune-privileged artificial pancreas #isletSC-1,
3. SCOS test kit #scoGo .
The developing products have entered the preclinical stage of animal trials and preparing for human clinical trials. At present, the company welcome talents who are aspiring to promote immune-privileged cell therapy with medical industry & cell therapy background to join us!
